766515-34-8

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-5-iodopyridine-3-carbonitrile is used as a chemical intermediate for the synthesis of complex compounds, which are often useful in medicinal chemistry. Its unique structure allows for the development of new drugs and therapeutic agents.
Used in Chemical Research:
2-Chloro-5-iodopyridine-3-carbonitrile is used as a research compound in the field of chemical research. Its distinct structure and properties make it a valuable tool for studying chemical reactions and transformations, contributing to the advancement of scientific knowledge.
Used in Material Science:
2-Chloro-5-iodopyridine-3-carbonitrile is used as a building block in the development of new materials. Its unique structure and properties may enable the creation of novel materials with specific characteristics, such as improved stability or enhanced reactivity, for various applications in material science.

Upstream product

• 766515-33-7 3-cyano-2-hydroxy-5-iodopyridine 
• 6602-54-6 2-chloro-3-pyridinecarbonitrile 
• 20577-27-9 2-hydroxy-3-cyanopyridine 

Downstream Products

• 766515-35-9 1-methyl-3-amino-5-iodo-1H-pyrazolo[3,4-b]pyridine 
• 1392151-89-1 5-(3,5-difluorophenyl sulfinyl)-1H-pyrazolo[3,4-b]pyrazin-3-amine 
• 1392151-92-6 5-[(3,5-difluorophenyl)sulfonyl]-1H-pyrazolo[3,4-b]pyrazin-3-amine 
• 1392151-76-6 1-(5-((3,5-difluorophenyl)thio)-1H-pyrazolo[3,4-b]pyridin-3-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl)thiourea 
• 1392151-64-2 N-(5-((3,5-difluorophenyl)thio)-1H-pyrazolo[3,4-b]pyrazin-3-yl)-4-(4-methylpiperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzamide 
• 1392151-65-3 N-(5-(3,5-difluorophenylthio)-1-(4-(4-methylpiperazine-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido) benzoyl)-1H-pyrazolo[3,4-b]pyrazine-3-yl)-4-(4-methylpiperazine-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzamide 
• 1392150-08-1 5-[(3,5-difluorophenyl)thio]-1H-pyrazolo[3,4-b]pyrazin-3-amine 
• 766515-38-2 1-methyl-3-(2,2-dimethyl-propionamido)-5-phenylethynyl-1H-pyrazolo[3,4-b]pyridine 
• 766515-39-3 (E)-1-methyl-3-(2,2-dimethyl-propionamido)-5-styryl-1H-pyrazolo[3,4-b]pyridine 
• 766515-40-6 1-methyl-3-(2,2-dimethyl-propionamido)-5-phenyl-1H-pyrazolo[3,4-b]pyridine 
• 766515-45-1 1-methyl-3-iodo-5-phenylethynyl-1H-pyrazolo[3,4-b]pyridine 
• 766515-42-8 1-methyl-3-amino-5-phenylethynyl-1H-pyrazolo[3,4-b]pyridine 

Relevant academic research and scientific papers

Derivatives of azaindoles or diazaindoles for treating pain

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; for use in the treatment of pain.

DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; for use in the treatment of pain.

DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING TRK

The present invention relates to a compound of following formula (I) or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein.

Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein.

DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; as well as to the use of same as a drug, notably intended for the treatment of cancer, inflammation and neurodegenerative diseases such as Alzheimer's disease; to the use of same as a kinase inhibitor; to the pharmaceutical compositions comprising same; and to methods for the preparation of same.

DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; as well as to the use of same as a drug, notably intended for the treatment of cancer, inflammation and neurodegenerative diseases such as Alzheimer's disease; to the use of same as a kinase inhibitor; to the pharmaceutical compositions comprising same; and to methods for the preparation of same.

Synthesis of 3,5-difunctionalized 1-methyl-1H-pyrazolo[3,4-b]pyridines involving palladium-mediated coupling reactions

Indirect iodination of 2-chloro-nicotinonitrile gave 2-chloro-5- iodonicotinonitrile, which was cyclized with methylhydrazine to lead to 3-amino-5-iodopyrazolo[3,4-b]pyridine. Position 3 was then protected by pivaloyl group and the resulting 5-iodo-3-pivaloylaminopyrazolo[3,4-b]pyridine was engaged in palladium-promoted coupling reactions with various reagents to give 3-pivaloylamino-5-substituted compounds. Deprotection and iododediazoniation followed by cross-coupling reactions in position 3 afforded novel unsymmetrical 3,5-disubstituted pyrazolo[3,4-b]pyridine species.